Wall Street analysts expect that Xenon Pharmaceuticals Inc (NASDAQ:XENE) will report earnings of ($0.49) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Xenon Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.41) and the lowest estimate coming in at ($0.61). Xenon Pharmaceuticals reported earnings of ($0.33) per share in the same quarter last year, which suggests a negative year over year growth rate of 48.5%. The company is expected to announce its next quarterly earnings report on Tuesday, November 5th.
On average, analysts expect that Xenon Pharmaceuticals will report full year earnings of ($1.88) per share for the current year, with EPS estimates ranging from ($2.18) to ($1.68). For the next fiscal year, analysts expect that the business will report earnings of ($1.92) per share, with EPS estimates ranging from ($2.39) to ($1.58). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Xenon Pharmaceuticals.
Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.46) by $0.09.
XENE traded down $0.07 during trading on Friday, hitting $9.25. The company’s stock had a trading volume of 20,600 shares, compared to its average volume of 80,486. The firm’s 50 day moving average price is $9.25 and its 200-day moving average price is $9.50. The company has a debt-to-equity ratio of 0.18, a current ratio of 11.07 and a quick ratio of 11.07. The stock has a market cap of $240.05 million, a PE ratio of -6.95 and a beta of 1.33. Xenon Pharmaceuticals has a twelve month low of $5.41 and a twelve month high of $14.45.
Institutional investors and hedge funds have recently modified their holdings of the business. Sphera Funds Management LTD. raised its holdings in Xenon Pharmaceuticals by 18.7% in the 1st quarter. Sphera Funds Management LTD. now owns 533,655 shares of the biopharmaceutical company’s stock valued at $5,422,000 after acquiring an additional 84,171 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Xenon Pharmaceuticals by 18.9% during the 4th quarter. Northern Trust Corp now owns 12,246 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 1,948 shares during the last quarter. NEA Management Company LLC acquired a new stake in shares of Xenon Pharmaceuticals during the 2nd quarter worth $1,802,000. Altshuler Shaham Ltd increased its holdings in shares of Xenon Pharmaceuticals by 4.3% during the 2nd quarter. Altshuler Shaham Ltd now owns 149,758 shares of the biopharmaceutical company’s stock worth $1,477,000 after buying an additional 6,151 shares during the last quarter. Finally, Athanor Capital LP acquired a new stake in shares of Xenon Pharmaceuticals during the 2nd quarter worth $100,000. Institutional investors own 68.26% of the company’s stock.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals, Inc engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P.
Featured Article: What are trading strategies for the 52-week high/low?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.